Analytical Data
-
Gene name
DEFB4A
- Application
-
Alternative Names
DEFB4A；DEFB102；Defensin beta 4A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15263
-
Expression Region
24-64aa
-
AA Sequence
GIGDPVTCLK SGAICHPVFC PRRYKQIGTC GLPGTKCCKK P
-
Molecular Weight
4.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEFB4A, or Defensin Beta 4A, is a member of the defensin family, which includes small cationic peptides known for their antimicrobial properties. Research into DEFB4A has garnered interest due to its critical role in the immune response, particularly within the epithelium, where it functions as a first line of defense against pathogens. Its expression is notably upregulated in various inflammatory conditions and infections, suggesting a protective role against bacterial, viral, and fungal pathogens. Studies indicate that DEFB4A not only exhibits direct antimicrobial activity but also modulates innate and adaptive immune responses, making it a potential target for therapeutic interventions. The recombinant protein version of DEFB4A is being investigated for its potential applications in developing new antimicrobial agents or enhancing wound healing processes. Additionally, understanding the molecular mechanisms governing the activity and regulation of DEFB4A can provide insights into its dual role in immunity and inflammation, paving the way for novel strategies in treating infectious diseases or inflammatory disorders. The ongoing research is crucial for comprehensively understanding its biological significance, which could translate into clinical applications in the fields of immunology and infectious disease management.
